Hepatic adverse events with CDK4/6 inhibitors: a systematic review combining meta-analysis and FAERS database

CDK4/6is increase the risk of hepatotoxicities in patients with BC. Palbociclib, ribociclib, and abemaciclib caused liver damage, while dalpiciclib did not. The most common manifestations were elevated ALT and AST levels.